Suzetrigine is under clinical development by Vertex Pharmaceuticals and currently in Phase II for Diabetic Peripheral Neuropathy. According to GlobalData, Phase II drugs for Diabetic Peripheral Neuropathy have an 11% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Suzetrigine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Suzetrigine overview

VX-548 is under development for the treatment of post-operative pain (acute pain), diabetic peripheral neuropathy and painful lumbosacral radiculopathy (PLSR). The drug candidates act by targeting sodium channel protein type 10 subunit alpha.

Vertex Pharmaceuticals overview

Vertex Pharmaceuticals (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for the treatment of cystic fibrosis. Through its research and development efforts, the company focuses on cystic fibrosis, sickle cell diseases, beta thalassemia, type-1 diabetes and pain. It uses state-of-the-art technology platforms to discover new disease targets, compounds, delivery mechanisms, and treatment modalities. Vertex has R&D centers and commercial offices in North America, South America, Europe, and Australia. The company offers its products in the US, Europe, Australia, and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

For a complete picture of Suzetrigine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.